Natalia Vtyurina on Quality 5.0, Advanced Therapies and LEF Leadership

Pharma Now: Your career spans advanced therapies, quality operations, and public affairs. What key experiences shaped your journey in the pharmaceutical industry?

Ms. Natalia: My journey has been shaped by working at the intersection of science, research, manufacturing, and regulation. With a background in bionanoscience and nanomedicine, I have always been fascinated by how fundamental research translates into real therapies. Moving into the pharmaceutical industry allowed me to experience how innovation is transformed into products that ultimately reach patients.

My experience in COVID-19 vaccine manufacturing, followed by work in advanced cell therapy production, highlighted the critical importance of strong quality systems, cross-functional collaboration, and regulatory alignment in delivering complex therapies safely and reliably.

At the same time, serving as Chair of the Works Council provided me with a unique perspective on how organizational decisions impact employees on the work floor. These experiences reinforced my belief that successful innovation requires not only technical excellence, but also trust, transparency, and strong collaboration across departments, with leadership and Quality playing a key role in helping breaking silos.

To broaden my perspective, I pursued training in Public Affairs, which deepened my understanding of the pharmaceutical industry beyond manufacturing. It highlighted the interaction between industry, healthcare systems, and policy, as well as the influence of government and public stakeholders on strategic decision-making. This has shaped my ambition to contribute more broadly within the healthcare ecosystem, potentially at a governmental level, combining my experience in manufacturing, access to innovation, and the role of policy in bringing therapies to patients.

Pharma Now: You have worked on large initiatives such as COVID-19 vaccine supply and cell therapy manufacturing. What lessons from those projects influenced your approach to quality and innovation?

Ms. Natalia: One key lesson is that quality must be proactive and embedded at every stage of development and manufacturing. During the COVID-19 pandemic, the urgency to scale vaccine production demonstrated how essential transparent communication, cross-functional collaboration, and expertise are under pressure.

The vaccine supply effort also showed how quickly the industry can mobilize when there is a shared purpose, highlighting the importance of resilient supply chains, cross-organizational collaboration, and agile decision-making, all while maintaining strict quality standards.

In cell therapy manufacturing, I learned that innovation and quality must evolve together, especially for highly personalized and complex products. This requires flexibility, strong knowledge and risk management, and a culture of continuous learning to keep up controls, as traditional manufacturing frameworks often need to adapt while ensuring the same level of safety and reliability.

Pharma Now: You are deeply involved in building professional communities through ISPE and other initiatives. What motivated you to focus on community building within the life sciences sector?

Ms. Natalia: The life sciences sector faces complex scientific, regulatory, and societal challenges that no single organization can solve alone. Community building creates a platform where professionals can exchange knowledge, learn from each other’s experiences, and collectively improve industry standards and good working practices, while openly discussing emerging challenges.

It also plays an important role in growing the next generation of pharma professionals, helping them navigate their careers, develop future-relevant skills, accelerating their contribution within the industry and remain competitive in a rapidly evolving job market.

Organizations like ISPE are particularly powerful in this space, as they bring together manufacturing companies, regulators, SMEs, and experts across science, engineering, and technology.

My motivation is driven by the belief that collaboration across industry, academia, regulators, and policy stakeholders accelerates responsible innovation and strengthens the overall ecosystem. Ultimately, strong collaboration not only drives innovation but also reinforces a robust quality culture across the sector.

Just because trust and integrity are the best policies ever within any organization.

Pharma Now: At the Pharma & Biotech Quality Summit, many discussions focus on the future of quality in advanced therapies. How do you see quality systems evolving for cell and gene therapy manufacturing?

Ms. Natalia: Advanced therapies involve complex biological processes and highly personalized manufacturing models that differ significantly from traditional pharmaceuticals. As a result, quality systems must evolve to become more adaptive, flexible, data-driven, and integrated with digital technologies.

These therapies often involve small batch sizes, complex supply chains, and patient-specific production, leaving little room for deviation or risk to patient safety. This requires stronger integration of real-time data monitoring, digital tools, and risk-based quality management.

At the same time, closer collaboration between manufacturing, MSAT, quality, and supply chain teams is essential, supported by more adaptive regulatory approaches.

While innovation accelerates, regulatory alignment and a strong, integrated quality culture remain fundamental. Ultimately, quality systems themselves must become more innovative — enabling technological progress while consistently ensuring the highest standards of patient safety.

Pharma Now: You will be speaking at the summit. What key insight or perspective are you most excited to share with fellow industry leaders?

Ms. Natalia: I am particularly excited to discuss the importance of human-centered innovation in quality systems, especially in the context of Future-Proof Manufacturing through Quality 5.0. As digitalization, automation, and AI reshape manufacturing, it is essential that people remain at the center of these transformations.

Drawing on my experience from both an industrial and employee representation perspective, I advocate for an Industry 5.0 approach, where quality maturity becomes the foundation — strengthening culture, knowledge flow, and leadership accountability while driving sustainability, resilience and human-centricity.

A key enabler is creating an Integrated Environment, where HR, QA, Works Councils, and leadership collaborate to make aligned and responsible decisions. Engaging operators, quality professionals, and cross-functional teams early leads to better implementation, stronger compliance, and more sustainable outcomes. This includes thoughtful change management, ensuring trust, knowledge retention, and workforce stability, while actively supporting reskilling and preparing employees for digital transformation.

At the same time, the role of quality professionals is evolving — from guardians of compliance to knowledgeable experts in emerging technologies, acting as facilitators and first-line enablers of innovation. This positions Quality as a strong partner to leadership, enabling predictive quality, better decision-making, and higher organizational maturity.

To unlock this potential, organizations must integrate Knowledge Management (KM) and Quality Risk Management (QRM). Anchored in the Risk–Knowledge Infinity (RKI) Cycle, risk-based decisions generate and strengthen product and process knowledge, transforming tools like PQR and process verification into valuable sources of insight.

Ultimately, this approach positions Quality not just as a control function, but as a strategic driver of performance, innovation, resilience, and long-term cost efficiency.

Pharma Now: Events like this bring together professionals from across the pharmaceutical ecosystem. Why do you believe such platforms are important for advancing quality practices globally?

Ms. Natalia: Quality challenges in the pharmaceutical industry are often shared across companies and regions — and clear patterns emerge across the broader ecosystem. Platforms such as conferences and professional forums create opportunities for experts to exchange practical insights, align on best practices, and learn from both successes and failures.

Ms. Natalia: They also enable professionals to engage with different perspectives across departments, organizations, and functions, strengthening communication and collaboration within their own organizations.

Global platforms are particularly important for advanced therapies, where many challenges are universal. Collaboration between industry, regulators, and experts accelerates the development of best practices, strengthens trust, and helps the industry evolve more effectively.

Ultimately, this collective learning improves outcomes for patients worldwide.

Pharma Now: As the Chair of the Quality Community of Practice, how do you encourage collaboration and knowledge sharing among quality professionals?

Ms. Natalia: Creating a safe environment for open dialogue is essential. In our community, we encourage members to share both successes and challenges, as real learning often comes from discussing difficulties.

We focus on connecting professionals from different disciplines — including SMEs, manufacturing, QA and QP professionals, leadership, and regulatory stakeholders — so that solutions are developed from multiple perspectives.

Through structured discussions, case-based learning, and cross-sector dialogue, we enable participants to learn from each other, build collective knowledge, and strengthen collaboration across the Quality ecosystem.

The pharmaceutical industry is undergoing rapid transformation with digitalization and new therapies. How can quality leaders stay ahead while maintaining strong compliance?

Not only quality leaders, but also senior leadership must evolve toward a more people-driven, less hierarchical leadership style, investing in knowledgeable and skilled employees aligned with increasing technological demands.

They need to combine technical expertise with accountability and strategic thinking, and embrace what I would call LEF leadership — courageous, authentic, and value-driven. LEF leadership means stepping beyond conventional approaches, taking responsibility, and making difficult decisions grounded in integrity and purpose.

It requires openness to hear about issues and challenges, vulnerability, tolerance for critical feedback, and a realistic view — balancing optimism with the courage to acknowledge when things are going wrong — as well as the ability to have honest conversations. This fosters a culture of trust, psychological safety, and continuous improvement.

In a rapidly transforming industry, this type of leadership enables organizations to shift from reactive decision-making to proactive, sustainable transformation. To stay ahead, quality leaders must remain curious, adaptable, and continuously learning, while building strong digital capabilities and fostering collaboration across technical, regulatory, and operational teams.

Ultimately, success lies in balancing innovation with responsibility, where leadership empowers people and Quality becomes a true enabler of progress.

Pharma Now: From your perspective, what skills will be most critical for the next generation of pharma quality professionals?

Ms. Natalia: Future quality professionals will need a strong combination of technical expertise and digital literacy, alongside the ability to communicate effectively, collaborate across functions, and learn quickly from different perspectives while remaining open and curious.

Equally important is integrity — acting with honesty, accountability, and consistency, even in complex and high-pressure environments, and making decisions that prioritize patient safety above all.

Critical thinking will be essential — including the confidence to ask the right questions, understand diverse interests and viewpoints, and “turn them like a disco ball”: analyzing multiple angles to approach challenges in a structured, solution-oriented way.

They must be comfortable working with data, understanding advanced technologies, and operating in interdisciplinary environments. Alongside regulatory knowledge, skills in data analysis, digital tools, and stakeholder collaborationwill become increasingly important.

Above all, the ability to navigate complex innovation while maintaining a strong patient-centric mindset will be key to ensuring both progress and safety in the evolving pharmaceutical landscape.

Rapid-Fire Round

Pharma Now: Quality culture in one word

Ms. Natalia: Integrity

Pharma Now: Biggest challenge in pharma quality today

Ms. Natalia: Managing rapid innovation while maintaining robust compliance

Pharma Now: One technology shaping the future of quality

Ms. Natalia: Digital manufacturing and real-time data analytics

Pharma Now: A habit every quality leader should develop

Ms. Natalia: Continuous learning and open dialogue with teams

Pharma Now: The future of advanced therapies in one sentence

Ms. Natalia: Advanced therapies will transform medicine through highly personalized treatments, but their success will depend on robust, innovative, and adaptable quality systems supported by strong global collaboration.